Clinical trials in a dish (CTiD)

Our translational platform can support your preclinical drug development by helping you select a candidate from your lead compound library. HUB Organoids are patient-derived models that preserve original tissue morphology and pathophysiology. Importantly they accurately predict patient response in the clinic and therefore can be effectively used as patient avatars in Phase II-like “clinical trials in a dish” (CTiD) to stratify your patient population. HUB Organoids allow you to:

  • Assess drug efficacy across a broad number of models to identify your target patient population
  • Discover a new target patient population
  • Probe mechanisms of action
  • Test combination strategies
  • Identify biomarkers of response or non-response
  • Test off-target toxicity on healthy organoids

HUB Organoids preserve the original patient genetic make-up in culture indefinitely, allowing you to connect genomic heterogeneity and gene function to in vitro drug responsiveness for the development of a road map for improved treatment strategies.

The importance of a living biobank of models

Our biobank represents the main pillar of our CTiD translational platform as it is a living repository of patient-derived models that recapitulates the heterogeneity of the patient population.

Established models include more than 1000 HUB Organoids derived from patients with monogenic diseases, cancer patients, or patients with other inflammatory conditions such as chronic inflammatory lung disease (COPD) and inflammatory bowel disease (IBD)

Our monogenic disease organoid collection includes:

  • Intestinal and lung organoids from Cystic Fibrosis (CF) patients representing more than 100 clinically-relevant mutations
  • Liver organoids from patients with metabolic diseases bearing alpha-1 antitrypsin deficiency or presenting Crigler-Najjar syndrome

The HUB living organoid biobank also has an important representation of cancer models including:

  • Multiple indications such as bladder, breast, colorectal, head and neck, intestinal, kidney, liver, lung, ovarian, and pancreatic tumour organoids
  • Patient-matched organoids derived from normal (cancer-free) adjacent tissue for a number of models to evaluate off target toxicities
  • Organoids derived from both primary and metastatic lesions from the same patient to investigate mechanisms of metastasis and response to treatment.

HUB Organoids can be selected from our biobank to explore novel therapeutic strategies and drug combinations before moving to clinical applications. The drug sensitivity data obtained in vitro via our CTiD can inform your patient stratification in preclinical studies, and be used in co-clinical applications as a predictive diagnostic tool to identify the best therapeutic strategy for each patient thus contributing to making personalised medicine a reality.

Co-clinical applications

HUB Organoids can support clinical trials in “co-clinical” applications whereby organoids are developed from patient biopsies while they are enrolled in a clinical trial (Phase I to III). In this settings HUB Organoids are treated similarly to patients in the clinic to:

  • prospectively identify responders and non-responders in subsequent trials or after market entry
  • investigate the mechanism of response or lack of response in patients


Personalized medicine

The development of next-generation sequencing has contributed to shifting the focus from a “drug-centric” to a “patient-centric” view of therapeutic development whereby each patient is treated with a personalised approach, tailored to the molecular pathology of their disease. HUB Organoid Technology is contributing to making personalized medicine a reality for an increasing number of patients by faithfully recapitulating patient disease in vitro with organoid models that can be established directly from patient tissue and propagated for drug testing in a matter of weeks.

HUB Organoids have already been used as predictive diagnostic tools in cystic fibrosis where patient have been successfully treated based upon pharmacology data from corresponding organoid models.



Have any questions?

contact us